2027, FDA and Immunization - Pharmacy Technician Pulse

Social Media Significantly Influences Attitudes, Behaviors Toward Skin Health

Drug Topics

JUNE 13, 2025

billion people used social media in 2021, and this number is likely to grow to almost 6 billion in 2027. FDA Approves Roflumilast Foam For Plaque Psoriasis of Scalp, Body Ashley Gallagher May 22nd 2025 Article The supplemental new drug application for roflumilast (Zoryve) is approved for adult and pediatric patients 12 years and older.

Specialty Pharmacies

Specialty Pharmacies Compounding Independent Pharmacies Immunization

FDA approves Wezlana for inflammatory conditions

The Checkup by Singlecare

NOVEMBER 6, 2023

Food and Drug Administration (FDA) just approved Wezlana (ustekinumab-auub), a biosimilar for the popular drug Stelara. According to the FDA announcement, the most serious side effect of Wezlana is infection because the prescription affects your immune response.

FDA

FDA Immunization

Treatment options for Crohn’s disease expand after Rinvoq approval

Pharmaceutical Technology

MAY 19, 2023

The US Food and Drug Administration (FDA) has approved AbbVie’s Rinvoq (upadacitinib) for patients with Crohn’s disease who do not respond to TNF blockers, a common immune suppressant treatment for the condition. The FDA nod means Rinvoq is now approved for seven indications in gastroenterology, rheumatology and dermatology.

Mayo Clinic

Mayo Clinic Dosage FDA Immunization

Transforming oncology with antibody therapeutics

European Pharmaceutical Review

MAY 4, 2023

According to Research and Markets 8 , the market for bispecific antibodies for cancer is forecasted to grow by $400 million during 2022-2027, due to the increasing prevalence of cancer worldwide. Overall, the mechanisms of action for amivantamab include ligand blocking, receptor degradation, and immune cell-mediated activity.

Immunization

Immunization Chemotherapy FDA

Provention finally gets FDA nod for type 1 diabetes drug teplizumab

pharmaphorum

NOVEMBER 18, 2022

At its second attempt, Provention Bio has secured FDA approval for teplizumab, as a treatment to delay late-stage type 1 diabetes (T1D) in at-risk individuals – becoming the first disease-modifying therapy for these patients. It is now in line for a $35 million equity investment by Sanofi following FDA approval.

FDA

FDA Immunization

Future of Bispecific Antibody: Exploring the Rise in Approvals

Roots Analysis

OCTOBER 4, 2023

They are designed to recognize and bind to two specific molecules, such as a tumor cell and an immune cell, or two different parts of the same molecule. During the research, I noticed a significant increase in the number of FDA approvals for bispecific antibodies in recent years. during the period 2023-2035.

Chemotherapy

Chemotherapy Immunization FDA

Moving towards oral delivery of biologics

European Pharmaceutical Review

FEBRUARY 22, 2023

Of the 175 new drugs approved by the US Food and Drug Administration (FDA) between 2016 and 2019, most were biologics. 2 Most biotherapeutics are delivered parenterally, with some exceptions being ocular or inhaled formulations. 5 Overall, these factors result in biopharmaceuticals having oral bioavailability of less than one percent.

Immunization

Immunization Packaging Labelling FDA

The future of targeted alpha therapy development and manufacture

European Pharmaceutical Review

MARCH 7, 2024

billion between 2022 to 2027. Firstly, alpha particles exhibit greater biological effectiveness by inducing irreparable DNA double-strand breaks, minimising the risk of resistance or immune escape in tumour cells. However, by employing alpha particles, TAT offers two crucial advantages.

Pharmaceutical Companies

Pharmaceutical Companies Pharmaceutical Companies Immunization FDA

FDA Approves Immunoglobulin Formulation With Low IgA Content for Primary Immunodeficiency

Pharmacy Times

JULY 7, 2025

Takeda will discontinue Gammagard S/D by December 2027, transitioning to the new low IgA formulation. SHOW MORE The new formulation contains little immunoglobulin A, reducing possible risks associated with infusion in patients with primary immunodeficiency.

FDA

FDA Immunization Compounding Pharmacies Compounding

Covid-19 vaccine success bolsters nanoparticle drug delivery research

Pharmaceutical Technology

APRIL 24, 2023

Covid-19 vaccines from Moderna and Pfizer /BioNTech, which use lipid nanoparticles, became the only two FDA-approved vaccines for almost all ages. However, after a period of slow movement in the field, the FDA approved the first nanodrug, Doxil, for Kaposi sarcoma in 1995. This design protects antibodies from the innate immune system.

Vaccines

Vaccines Immunization Medical Schools FDA

Taletrectinib Gains FDA Approval for Locally Advanced or Metastatic ROS1+ NSCLC

Pharmacy Times

JUNE 11, 2025

The FDA approved taletrectinib (Ibtrozi; Nuavtion Bio Inc) for the treatment of adult patients with locally advanced or metastatic ROS1-positive (ROS1+) non–small cell lung cancer (NSCLC). It demonstrated high response rates with durable benefit and intracranial activity and was well-tolerated among patients, according to the FDA.

FDA

FDA Compounding Pharmacies Immunization Hospitals

FDA approves Takeda’s Gammagard liquid ERC for primary immunodeficiency

Pharmaceutical Technology

JULY 1, 2025

The US Food and Drug Administration (FDA) has approved Takeda’s new immunoglobulin (IG) therapy, Gammagard liquid ERC [immune globulin infusion (human)], to treat primary immunodeficiency (PI) in individuals aged two years and above. Credit: HenadziPechan/Shutterstock. Don’t let policy changes catch you off guard.

FDA

FDA Packaging Communication Hospitals

Astellas licenses companion drug for Pompe gene therapy

pharmaphorum

JANUARY 10, 2023

Other IgG proteases are being developed to tackle the issue of pre-existing immunity against AAV, but according to Selecta chief executive Carsten Brun these tend to be derived from common human pathogens – which means they themselves can be the target of existing antibodies. .”

Immunization

Immunization FDA

Delivery systems for biologics

European Pharmaceutical Review

MARCH 4, 2024

Indeed, in 2022, biologics constituted 40 percent of all US Food and Drug Administration (FDA) approved drugs, projecting a compound annual growth rate (CAGR) of 9.5 percent through 2027. He was on the faculty of Johns Hopkins Medicine and served as a medical officer with the US/HHS FDA before joining KCR.

FDA

FDA Vaccines Immunization Compounding

Contamination Trends & Proposed Solutions

ISPE

MARCH 8, 2023

Identification and Analysis of Contamination Trends Three major recall databases—those of the US FDA, the United Kingdom’s Medicine and Healthcare Products Regulatory Agency (UK MHRA), and Australia’s Therapeutic Goods Administration (TGA)—were searched to assess contamination trends in the past five years. 6 (2018): 649–655.

Compounding

Compounding Compounding Pharmacies Packaging FDA

Pharmacy Technician Pulse

Social Media Significantly Influences Attitudes, Behaviors Toward Skin Health

FDA approves Wezlana for inflammatory conditions

Trending Sources

Treatment options for Crohn’s disease expand after Rinvoq approval

Transforming oncology with antibody therapeutics

Provention finally gets FDA nod for type 1 diabetes drug teplizumab

Future of Bispecific Antibody: Exploring the Rise in Approvals

Moving towards oral delivery of biologics

The future of targeted alpha therapy development and manufacture

FDA Approves Immunoglobulin Formulation With Low IgA Content for Primary Immunodeficiency

Covid-19 vaccine success bolsters nanoparticle drug delivery research

Taletrectinib Gains FDA Approval for Locally Advanced or Metastatic ROS1+ NSCLC

FDA approves Takeda’s Gammagard liquid ERC for primary immunodeficiency

Astellas licenses companion drug for Pompe gene therapy

Delivery systems for biologics

Contamination Trends & Proposed Solutions

Stay Connected